New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
08:25 EDTROIL, ROIL, PFIE, PFIE, ARSD, ARSD, UUUU, UUUU, SRNE, SRNE, VTEQ, VTEQ, SNWV, SNWV, OPXA, OPXA, CGIX, CGIX, GALT, GALT, OGEN, OGENRedChip Companies to hold a virtual conference
RedChip Virtual Conference to be held on April 23-24 with webcasted company presentations to begin on April 23 at 8:30 am. Webcast Link
News For OGEN;GALT;CGIX;OPXA;SNWV;VTEQ;SRNE;UUUU;ARSD;PFIE;ROIL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2015
08:36 EDTOPXACryoport to support Opexa Therapeutics' T-cell immunotherapy programs
Cryoport's (CYRX) validated cryogenic logistics solution will support future clinical trials for Opexa Therapeutics' (OPXA) lead personalized T-cell immunotherapy programs for Multiple Sclerosis and Neuromyelitis Optica. Cryoport's global distribution network will provide the necessary cryogenic logistics support between Opexa and its clinical sites.
August 13, 2015
08:17 EDTGALTGalectin receives patent notice of allowance for use of pectin compounds
Galectin Therapeutics said it received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application number 13/726,900, titled "Galactose-pronged polysaccharides in a formulation for antifibrotic therapies." When issued, the patent will extend coverage of the company's pectin-derived compounds, including broad molecular weight ranges and other sources of pectin, to include treatment of chronic kidney disease associated with the development of fibrosis, established kidney fibrosis, chronic lung disease associated with the development of fibrosis and established lung fibrosis. The company's lead compound, GR-MD-02, is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer that is comprised predominantly of galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. GR-MD-02 is currently in a Phase 2 program in subjects with non-alcoholic steatohepatitis with cirrhosis and NASH with advanced fibrosis.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use